Loading quotes...

Forecast

The analysts' average price target is €8.12 (+666.04%). The median is €8.12 (+666.04%).

Buy	13
Hold	2
Sell	1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

InflaRx shifts strategy toward kidney diseases and backs oral izicopan

InflaRx is shifting its focus from immunodermatology to complement-mediated kidney diseases and is positioning oral izicopan as its lead program, particularly for ANCA-associated vasculitis (AAV). The company plans a Phase IIb study in AAV for early 2025, is in talks with the FDA about efficacy endpoints, and sees market opportunities after the withdrawal of TAVNEOS in Europe. InflaRx reports financing through 2029 following a $150 million round, but continues to cite risks such as reaching agreement with the FDA, manufacturing preparations, and potential additional capital needs for later stages. » More on de.investing.com
InflaRx focuses on kidney diseases with INF904 as lead candidate

InflaRx is shifting its focus to ANCA-associated vasculitis and other kidney diseases and sees a larger market opportunity due to safety issues with avacopan. INF904 is presented as an orally available C5aR1 inhibitor with improved pharmacokinetics and a favorable liver safety profile compared with avacopan. Vilobelimab remains planned as a second, more rapidly available option for remission induction. The company is in discussions with the FDA about study design and endpoints and plans a phase II study with INF904; clinical and regulatory hurdles remain. » More on de.investing.com
InflaRx examines EMA approval pathways for AAV drugs Vilobelimab and Izicopan

InflaRx has opened talks with the EMA on possible approval routes in Europe for the anti‑C5a antibody Vilobelimab and the oral C5aR inhibitor Izicopan to treat ANCA‑associated vasculitis (AAV). The review follows the CHMP recommendation to withdraw the approval of Tavneos and aims to clarify the most efficient development path to make C5a/C5aR inhibitors available to patients. InflaRx describes Vilobelimab as phase‑3 ready after completion of two phase‑2 trials; phase‑2 planning for Izicopan will continue regionally. According to InvestingPro the stock has recently risen sharply, but the company reports a solid liquidity position with more cash than debt. » More on de.investing.com
InflaRx closes $150 million placement

InflaRx placed 75,000,000 common shares at $2.00 each, generating gross proceeds of $150 million before fees. The company said it will use the net proceeds to advance its product pipeline, for working capital and for general corporate purposes; new and existing institutional investors participated in the offering. According to InvestingPro, InflaRx is currently overvalued relative to its fair-value estimate and had negative free cash flow of $41.6 million over the past twelve months. » More on de.investing.com
InflaRx plans izicopan development for AAV and secures funding

InflaRx announces phase‑2 planning for the oral C5a receptor inhibitor izicopan in ANCA‑associated vasculitis (AAV) and is exploring accelerated development pathways. The company aims to generate proof‑of‑concept data for izicopan in additional complement‑mediated kidney diseases (aHUS, IgAN, C3G) in open‑label studies; initial clinical data are expected in 2027. Plans include a pharmacokinetic bridging study in China later this year, a capital‑markets day in summer 2026 and a webcast on May 8 to discuss strategy. InflaRx is pursuing a guaranteed capital increase of 75 million common shares at $2.00 each, with closing expected on May 7; proceeds are intended to fund programs to key milestones and operations through 2029. » More on de.investing.com

Financials

In the last quarter, InflaRx had revenue of €0 and net profit of -€2.44M

(EUR)	September 2026	YoY
Revenue	0	100.00%
Gross profit	-85.14K	462.33%
Net profit	-2.44M	80.10%
EBITDA	-2.34M	80.71%

Fundamentals

Metric	Value
Market capitalization	€173.43M
Number of shares	147.37M
52-week high/low	€2.66 - €0.72
Dividends	No
Beta	2.40
P/E ratio	-3.59
PEG ratio	-0.06
P/B ratio	1.19
P/S ratio	-5,065.34

Company profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.